Loading
The U.S. International Trade Commission instituted preliminary phase antidumping and countervailing duty investigations (Nos. 701-TA-797 and 731-TA-1793) on N-Cyclohexylbenzothiazole-2-sulfenamide (CBS) from China on May 12, 2026. The Commission will determine whether the US industry is materially injured or threatened by allegedly dumped and subsidized CBS imports, with a preliminary determination due by June 22, 2026. CBS is a rubber vulcanization accelerator classified under HTSUS subheadings 2934.20.80, 3812.10.10, and 3812.10.50.
The petition was filed with USITC triggering the mandatory 45-day statutory clock for a preliminary determination, placing June 22, 2026 as the binding procedural deadline. The structural driver is a pattern of AD/CVD actions targeting Chinese specialty chemical intermediates used in US manufacturing, consistent with sustained domestic-industry use of trade remedy statutes to counter Chinese pricing in upstream chemical markets.
The domestic CBS or rubber-chemicals manufacturing constituency is the petitioning coalition, using the statutory AD/CVD framework to obtain relief. The cross-pressure comes from downstream US rubber and tire manufacturers, who face higher input costs if duties are imposed and who may participate in the investigation as interested parties opposing a duty. This is a classic upstream-versus-downstream tension within US manufacturing, without meaningful congressional friction on the use of the AD/CVD mechanism itself.
China is the target country, and the investigation covers a specialty chemical (rubber vulcanization accelerator) where Chinese producers hold significant global market share. If duties are imposed, US importers will face pressure to source CBS from alternative suppliers in India, Europe, or other jurisdictions, though supply availability and price parity for non-Chinese CBS are not established in this record. No WTO challenge timeline is assessable at the preliminary stage, but an eventual AD/CVD order could draw a WTO dispute settlement filing by China consistent with its pattern on US trade remedy actions.